Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival
Background SLE is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell of origin (COO), with germinal centre B-cell (GCB) being more common and indicating better prognosis in the general population. We studied COO subtyping in patients with S...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-12-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/6/1/e000324.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846121516641550336 |
|---|---|
| author | Rosalind Ramsey-Goldman Diane L Kamen Eva Baecklund Basile Tessier-Cloutier David DW Twa Randy Gascoyne Nathalie A Johnson Carin Backlin Ann E Clarke Jennifer LF Lee Pedro Farinha Sasha Bernatsky |
| author_facet | Rosalind Ramsey-Goldman Diane L Kamen Eva Baecklund Basile Tessier-Cloutier David DW Twa Randy Gascoyne Nathalie A Johnson Carin Backlin Ann E Clarke Jennifer LF Lee Pedro Farinha Sasha Bernatsky |
| author_sort | Rosalind Ramsey-Goldman |
| collection | DOAJ |
| description | Background SLE is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell of origin (COO), with germinal centre B-cell (GCB) being more common and indicating better prognosis in the general population. We studied COO subtyping in patients with SLE diagnosed with DLBCL and their survival.Patients and methods We evaluated 20 cases of SLE with DLBCL. Immunohistochemistry analysis was performed (BCL2, MYC, BCL6, CD10, CD20, FOXP1, GCET1, MUM1) in tissue microarrays. We examined associations between molecular and clinical features, including overall survival.Results Of the 20 DLBCL SLE cases, 12/20 cases (60%) were classified as non-GCB using Hans or Choi algorithms. MYC and BCL2 protein expression was positive in 6/20 (30%) and 8/20 (40%) SLE cases, respectively, with 2/20 (10%) co-expressing both markers. Seven (7/20) had only extranodal involvement at DLBCL diagnosis. As expected, non-GCB cases had worse survival. Cases presenting exclusively with extranodal disease were associated with shorter SLE duration and better survival despite higher BCL2 protein expression.Conclusions We present novel data characterising DLBCL in SLE. Sixty per cent of the DLBCL in patients with SLE were non-GCB. The nodal and extranodal distribution in SLE was similar to what is known in the general population, but extranodal disease occurred more often with short SLE duration and was associated with longer overall survival. More research on cancer in SLE is the key to further understanding the complex interplay between cancer and the immune system. |
| format | Article |
| id | doaj-art-9c3e237f617f462eadca7a9b4ec1edfd |
| institution | Kabale University |
| issn | 2053-8790 |
| language | English |
| publishDate | 2019-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj-art-9c3e237f617f462eadca7a9b4ec1edfd2024-12-16T02:10:09ZengBMJ Publishing GroupLupus Science and Medicine2053-87902019-12-016110.1136/lupus-2019-000324Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survivalRosalind Ramsey-Goldman0Diane L Kamen1Eva Baecklund2Basile Tessier-Cloutier3David DW Twa4Randy Gascoyne5Nathalie A Johnson6Carin Backlin7Ann E Clarke8Jennifer LF Lee9Pedro Farinha10Sasha Bernatsky11Northwestern University Feinberg School of Medicine, Chicago, Illinois, USAMedical University of South Carolina, Charleston, South Carolina, USADepartment of Medical Sciences, Uppsala University, Uppsala, SwedenAnatomical Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, CanadaFaculty of Medicine, University of British Columbia, Vancouver, British Columbia, CanadaPathology Department and Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, CanadaDepartment of Medicine, Sir Mortimer B Davis Jewish General Hospital, Montreal, Québec, CanadaDepartment of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USACumming School of Medicine, University of Calgary, Calgary, Alberta, CanadaDivision of Clinical Epidemiology, McGill University Health Centre, Montreal, Québec, CanadaDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, CanadaCentre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, CanadaBackground SLE is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell of origin (COO), with germinal centre B-cell (GCB) being more common and indicating better prognosis in the general population. We studied COO subtyping in patients with SLE diagnosed with DLBCL and their survival.Patients and methods We evaluated 20 cases of SLE with DLBCL. Immunohistochemistry analysis was performed (BCL2, MYC, BCL6, CD10, CD20, FOXP1, GCET1, MUM1) in tissue microarrays. We examined associations between molecular and clinical features, including overall survival.Results Of the 20 DLBCL SLE cases, 12/20 cases (60%) were classified as non-GCB using Hans or Choi algorithms. MYC and BCL2 protein expression was positive in 6/20 (30%) and 8/20 (40%) SLE cases, respectively, with 2/20 (10%) co-expressing both markers. Seven (7/20) had only extranodal involvement at DLBCL diagnosis. As expected, non-GCB cases had worse survival. Cases presenting exclusively with extranodal disease were associated with shorter SLE duration and better survival despite higher BCL2 protein expression.Conclusions We present novel data characterising DLBCL in SLE. Sixty per cent of the DLBCL in patients with SLE were non-GCB. The nodal and extranodal distribution in SLE was similar to what is known in the general population, but extranodal disease occurred more often with short SLE duration and was associated with longer overall survival. More research on cancer in SLE is the key to further understanding the complex interplay between cancer and the immune system.https://lupus.bmj.com/content/6/1/e000324.full |
| spellingShingle | Rosalind Ramsey-Goldman Diane L Kamen Eva Baecklund Basile Tessier-Cloutier David DW Twa Randy Gascoyne Nathalie A Johnson Carin Backlin Ann E Clarke Jennifer LF Lee Pedro Farinha Sasha Bernatsky Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival Lupus Science and Medicine |
| title | Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival |
| title_full | Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival |
| title_fullStr | Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival |
| title_full_unstemmed | Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival |
| title_short | Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival |
| title_sort | cell of origin in diffuse large b cell lymphoma in systemic lupus erythematosus molecular and clinical factors associated with survival |
| url | https://lupus.bmj.com/content/6/1/e000324.full |
| work_keys_str_mv | AT rosalindramseygoldman celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT dianelkamen celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT evabaecklund celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT basiletessiercloutier celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT daviddwtwa celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT randygascoyne celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT nathalieajohnson celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT carinbacklin celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT anneclarke celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT jenniferlflee celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT pedrofarinha celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival AT sashabernatsky celloforiginindiffuselargebcelllymphomainsystemiclupuserythematosusmolecularandclinicalfactorsassociatedwithsurvival |